INTRODUCTION
NAFLD, NASH, weight loss
CHRONIC LIVER DISEASE
In the absence of an approved drug therapy or cure, lifestyle intervention with the goal of modest body weight loss continues to be the foundation of clinical management in patients with NAFLD, a leading cause of chronic liver disease worldwide.There is a clear unmet need to develop effective lifestyle intervention programs that can address each of these barriers and empower patients with NAFLD to lead a healthy lifestyle. Such intervention programs need to consider the limitations of patients with NASH, the more severe type of NAFLD. Over the past several years, and forged out of necessity from the COVID-19 pandemic, telehealth and telemedicine have emerged at the forefront of clinical care. Each has been used to help improve the delivery of quality health care to patients with chronic liver disease.For these reasons, we conducted a randomized controlled pilot study to determine if a commercially available mHealth-delivered lifestyle intervention program can lead to clinically significant body weight loss in patients with NASH. We also determined the feasibility, acceptability, and safety of this widely accessible application.